Literature DB >> 11357180

Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by (13)C nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature.

Y Aso1, S Yoshioka, S Kojima.   

Abstract

To gain further insight into the effect of molecular mobility on the crystallization rate of amorphous drugs, the mean relaxation times of amorphous nifedipine and phenobarbital were calculated based on the Adam-Gibbs-Vogel (AGV) equation, using the parameters D, T(0), and T(f), derived from the heating rate dependence of the glass transition temperature (T(g)) of the amorphous drugs and heat capacity of the drugs in the amorphous and crystalline states. These relaxation times were compared with the crystallization rate of amorphous nifedipine and phenobarbital reported previously. The spin-lattice relaxation time (T(1)) and the spin-lattice relaxation time in the rotating frame (T(1rho)) of phenobarbital and nifedipine carbons were also determined. The temperature dependence of the crystallization rate of nifedipine and phenobarbital on the T(g) was coincident with that of the mean relaxation time calculated according to the AGV equation within experimental error, indicating that the crystallization of nifedipine and phenobarbital is largely correlated with molecular mobility at the temperatures studied. A (13)C nuclear magnetic resonance relaxation study indicated that the molecular motion of nifedipine and phenobarbital in the mid-kHz frequency range became significant at temperatures higher than T(g)-20 and T(g), respectively. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11357180     DOI: 10.1002/jps.1033

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  A practical method to predict physical stability of amorphous solid dispersions.

Authors:  Stéphanie Greco; Jean-René Authelin; Caroline Leveder; Audrey Segalini
Journal:  Pharm Res       Date:  2012-03-16       Impact factor: 4.200

2.  Comparison of molecular mobility in the glassy state between amorphous indomethacin and salicin based on spin-lattice relaxation times.

Authors:  Katsuhiko Masuda; Sachio Tabata; Yasuyuki Sakata; Tetsuo Hayase; Etsuo Yonemochi; Katsuhide Terada
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

3.  Time-dependence of molecular mobility during structural relaxation and its impact on organic amorphous solids: an investigation based on a calorimetric approach.

Authors:  Chen Mao; Sai Prasanth Chamarthy; Rodolfo Pinal
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

4.  Effects of cooling rate on structural relaxation in amorphous drugs: elastically collective nonlinear langevin equation theory and machine learning study.

Authors:  Anh D Phan; Katsunori Wakabayashi; Marian Paluch; Vu D Lam
Journal:  RSC Adv       Date:  2019-12-04       Impact factor: 4.036

5.  A quantitative assessment of the significance of molecular mobility as a determinant for the stability of lyophilized insulin formulations.

Authors:  Sumie Yoshioka; Yukio Aso
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

6.  Preparation of a crystalline salt of indomethacin and tromethamine by hot melt extrusion technology.

Authors:  Mustafa Bookwala; Priyanka Thipsay; Samir Ross; Feng Zhang; Suresh Bandari; Michael A Repka
Journal:  Eur J Pharm Biopharm       Date:  2018-08-04       Impact factor: 5.571

7.  Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water.

Authors:  Patrick J Marsac; Hajime Konno; Alfred C F Rumondor; Lynne S Taylor
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 8.  The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.

Authors:  Khadijah Edueng; Denny Mahlin; Christel A S Bergström
Journal:  Pharm Res       Date:  2017-05-18       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.